Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4422019 | 0.83 | MEN1 (0.54) | MEN1KMT2AHSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL28574588 | 0.83 | ALDH1A1 (0.42) | MEN1KMT2AHSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL25242176 | 0.81 | MAPK8 (0.51) | CYP4F2CYP4A11SMN1; SMN2GSK3BDYRK1A | |
| SCHEMBL19808057 | 0.79 | ALDH1A1 (0.44) | MEN1KMT2AHSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL4360008 | 0.79 | ALDH1A1 (0.44) | MEN1KMT2AHSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL15219428 | 0.79 | MET (0.46) | MEN1KMT2AHSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL13060532 | 0.78 | HSP90AB1 (0.42) | KMT2AHSP90AB1ALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL20740304 | 0.78 | MET (0.44) | MEN1KMT2AHSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL15262697 | 0.78 | SMN1; SMN2 (0.42) | MEN1KMT2AHSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL9107401 | 0.78 | SMN1; SMN2 (0.42) | MEN1KMT2AHSD17B10ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724435-A1 | BIFUNCTIONAL AZINES CONJOGATES AS SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4673137-A1 | NBD1 MODULATORS AND METHODS OF USING THE SAME | Sionna Therapeutics Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20250188075-A1 | SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS | THE BROAD INSTITUTE, INC. | 2025-06-12 | — | — | US | disclosed |
| US-20250051344-A1 | BIFUNCTIONAL SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2024254532-A1 | BIFUNCTIONAL AZINES CONJOGATES AS SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| EP-4469457-A1 | SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS | The Broad Institute Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2024182736-A1 | NBD1 MODULATORS AND METHODS OF USING THE SAME | SIONNA THERAPEUTICS INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| WO-2023147015-A1 | SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS | THE BROAD INSTITUTE, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-9624200-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-04-18 | — | — | US | disclosed |
| US-20150087645-A1 | THERAPEUTIC PIPERAZINES | HELICON THERAPEUTICS, INC. | 2015-03-26 | — | — | US | disclosed |
| US-8927546-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2015-01-06 | — | — | US | disclosed |
| EP-2643000-A2 | THERAPEUTIC PIPERAZINES | Dart Neuroscience (Cayman) Ltd (KY) | 2013-10-02 | — | — | EP | disclosed |
| WO-2012040258-A2 | THERAPEUTIC PIPERAZINES | HELICON THERAPEUTICS, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012040258-A2 | THERAPEUTIC PIPERAZINES | HELICON THERAPEUTICS, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087645-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE4D | MEN1 4385/4885KMT2A 2021/4885HSD17B10 2919/4885 |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE4D | MEN1 4385/4885KMT2A 2021/4885HSD17B10 2919/4885 |
| US-20250051344-A1 | BIFUNCTIONAL SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | SMARCA2, SMARCE1, SMARCB1 | MEN1 1844/4885KMT2A 217/4885HSD17B10 2863/4885 |
| US-20250188075-A1 | SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS | CSNK1A1, CSNK2A1, CSNK1A1L | MEN1 1809/4885KMT2A 899/4885HSD17B10 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.